Filing Details
- Accession Number:
- 0001209191-18-025824
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-23 16:16:47
- Reporting Period:
- 2018-04-23
- Accepted Time:
- 2018-04-23 16:16:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1718108 | Surface Oncology Inc. | SURF | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1552293 | Edward S. Torres | 115 West Washington Street Suite 1680-South Indianapolis IN 46204 | No | No | Yes | No | |
1575852 | Lilly Ventures Fund I Llc | 115 West Washington Street Suite 1680-South Indianapolis IN 46204 | No | No | Yes | No | |
1602732 | Edward Steven Hall | 115 West Washington Street Suite 1680-South Indianapolis IN 46204 | No | No | Yes | No | |
1681884 | Lv Management Group, Llc | 115 West Washington Street Suite 1680-South Indianapolis IN 46204 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-04-23 | 3,181,817 | $0.00 | 3,181,817 | No | 4 | C | Indirect | By Fund |
Common Stock | Acquisiton | 2018-04-23 | 266,000 | $15.00 | 3,447,817 | No | 4 | P | Indirect | By Fund |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | By Fund |
No | 4 | P | Indirect | By Fund |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2018-04-23 | 7,000,000 | $0.00 | 3,181,817 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial publicoffering without payment or further consideration and had no expiration date.
- These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFIand has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the sharesheld by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee,which consists of S. Edward Torres, Dr. Steven E. Hall and Dr. Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaimsbeneficial ownership of the shares held by LVFI, except to the extent of his or its pecuniary interest therein. Dr. Shanafelt is a director of theIssuer and, accordingly, files separate Section 16 reports.